The STS/ACC TVT Registry data should alleviate prior concerns about the appropriateness of choosing TAVI for young patients.

The CLEAR-IE registry data, which show clinical efficacy, are just the first step—an RCT may be forthcoming, researchers say.

No matter whether patients had CAD or not, the simpler regimen was linked to less mortality and major bleeding at 6 months.

The technology is integrated with company’s electroanatomical mapping system, which helps guide operators during AF ablation.

At 2 years, the limb salvage rate was 65%, with “still very good wound healing out to 2 years in this group of patients, and ...

The diversion of blood flow through arterialization of the deep veins in the foot holds up well at 2 years as a therapy for ...

The heat-map data can be used at local levels to educate representatives about the amputation rates in their area.

The trial adds much-needed randomized data to an area where it’s been lacking. Questions about methods muddy interpretation.

The data thus far suggest fewer repeat interventions with the newly FDA approved resorbable device compared with PTA.

The trial was small and halted early, but investigators say the inflammatory hypothesis in TAVI is worth pursuing further.

The change reflects a growing understanding of what resources are needed to offer these scans and will likely improve access.

The data hint at sirolimus becoming a useful option or even a replacement for paclitaxel, but full 5-year follow-up is needed ...